HomeAI · summaries
Storia in 2 fonti
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely…
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
- ·
adnkronos.com
Aifa approva il rimborso di risankizumab per colite ulcerosa
AbbVie: 'Quarta indicazione rimborsata dal Ssn supportata da 2 ampi studi clinici'